ClinicalTrials.Veeva

Menu
C

Clinical Trials Center of Middle Tennessee | Franklin, TN

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Treprostinil
BI 1015550
Dupilumab
BLU-5937
Tempol
Deupirfenidone
SAR440340
Pomotrelvir
PBI-0451
Bexotegrast

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

16 of 24 total trials

A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough (CALM-2)

This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of BLU-5937 in participants with Refractory Chronic Cough (RCC).

Enrolling
Refractory Chronic Cough
Drug: Placebo
Drug: BLU-5937

This study is open to people with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF). They can only take part if they have c...

Enrolling
Progressive Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Drug: BI 1015550

HZNP-HZN-825-303 (HARBOR) comprises of 2 parts. Part 1 (Core Phase) is a randomized, double-blind, placebo-controlled, repeat-dose, multicenter trial...

Active, not recruiting
Idiopathic Pulmonary Fibrosis
Drug: HZN-825
Drug: Placebo

A randomized, double-blind, placebo-controlled clinical study to evaluate the safety and efficacy of 2 doses of inhaled pirfenidone (AP01) versus pla...

Enrolling
Progressive Pulmonary Fibrosis
Drug: AP01
Other: Placebo

This study will evaluate the efficacy and safety of astegolimab compared with placebo in participants with chronic obstructive pulmonary disease (COP...

Enrolling
Chronic Obstructive Pulmonary Disease (COPD)
Drug: Astegolimab
Drug: Placebo

This study is open to adults with a lung disease called Idiopathic Pulmonary Fibrosis (IPF). People can join the study if they are 40 years or older....

Active, not recruiting
Idiopathic Pulmonary Fibrosis
Drug: Placebo
Drug: BI 1015550

This study is open to adults with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs). People who have a form of PF-ILD other than Idiopathic...

Active, not recruiting
Lung Diseases, Interstitial
Drug: BI 1015550
Drug: Placebo

To compare the effect of daily oral dosing of leramistat over 12 weeks with placebo in participants aged 40 years or older with idiopathic pulmonary...

Enrolling
Idiopathic Pulmonary Fibrosis
Drug: Placebo
Drug: Leramistat

This study is open to adults 40 years or older with idiopathic pulmonary fibrosis (IPF). People can join the study if they are not on any treatment f...

Enrolling
Idiopathic Pulmonary Fibrosis
Drug: Placebo matching BI 1819479
Drug: BI 1819479

Study RIN-PF-302 is designed to evaluate the long-term safety and tolerability of inhaled treprostinil in subjects with idiopathic pulmonary fibrosis.

Invitation-only
Idiopathic Pulmonary Fibrosis
Interstitial Lung Disease
Device: Treprostinil Ultrasonic Nebulizer
Drug: Inhaled Treprostinil

This study a randomized, double-blind, four arm study to evaluate the safety and efficacy of LYT-100 compared to pirfenidone or placebo in adults wit...

Active, not recruiting
Idiopathic Pulmonary Fibrosis
Drug: Deupirfenidone
Drug: Placebo

A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of bexotegrast (PLN-74809) for the treatment o...

Enrolling
Idiopathic Pulmonary Fibrosis
Drug: PLN-74809
Drug: Placebo

Study RIN-PF-301 is designed to evaluate the superiority of inhaled treprostinil against placebo for the change in absolute forced vital capacity (FV...

Enrolling
Idiopathic Pulmonary Fibrosis
Interstitial Lung Disease
Drug: Inhaled Treprostinil
Drug: Placebo

Study RIN-PF-305 is designed to evaluate the safety and efficacy of inhaled treprostinil in subjects with progressive pulmonary fibrosis (PPF) over a...

Enrolling
Progressive Pulmonary Fibrosis
Interstitial Lung Disease
Device: Treprostinil Ultrasonic Nebulizer
Drug: Placebo

The primary objective of this study is to evaluate the safety and tolerability of oral daily administration of TTI-101 over a 12-week treatment durat...

Enrolling
Idiopathic Pulmonary Fibrosis
Drug: TTI-101
Drug: Placebo

Primary Objective:Primary population (former smokers cohort):* Evaluate the efficacy of itepekimab compared with placebo on the annualized rate of ac...

Active, not recruiting
Chronic Obstructive Pulmonary Disease
Drug: Placebo
Drug: Itepekimab SAR440340

Trial sponsors

Boehringer Ingelheim logo
Sanofi logo
United Therapeutics logo
B
A
Amgen logo
A
C
M
P

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems